在酒精使用障碍中GLP-1受体激活剂的影响
Mette Kruse Klausen1, Gitte Moos Knudsen2,3, Tina Vilsbøll2,4
1Psychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen University Hospital Frederiksberg, Frederiksberg, Denmark.
Basic & clinical pharmacology & toxicology
|February 1, 2025
概括
用于糖尿病和肥胖症的葡萄糖类-1受体激动剂 (GLP-1RAs) 显示出治疗酒精使用障碍 (AUD) 的希望. 研究包括临床前数据,病例研究和正在进行的临床试验,用于AUD治疗中的西马格卢提德.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 成 药物 药物 药物 药物
背景情况:
- 酒精使用障碍 (AUD) 是一个重大的公共卫生挑战,有效治疗方法有限.
- 类似葡萄糖-1 (GLP-1) 是一种内源性,参与葡萄糖调节和食欲控制.
- 已确立用于2型糖尿病和肥胖症的GLP-1受体激活剂 (GLP-1RAs) 正在成为AUD的潜在治疗剂.
研究的目的:
- 审查关于GLP-1RAs在治疗酒精使用障碍中的有效性现有证据.
- 巩固从临床前研究,病例报告,队列研究和神经成像中得出的发现.
- 突出GLP-1RAs作为AUD的新药学干预措施的潜力.
主要方法:
- 针对临床前研究的重点审查.
- 分析案例和基于登记的队列研究.
- 检查脑成像数据和对临床试验数据的二次分析.
主要成果:
- 临床前和临床初步数据表明GLP-1RAs在减少酒精消费和渴望方面可能发挥作用.
- 神经成像研究表明GLP-1RAs可能调节与奖励和成相关的大脑区域.
- 目前正在进行的临床试验正在调查特定的GLP-1RAs,如semaglutide,对AUD治疗疗效.
结论:
- GLP-1RAs代表了对酒精使用障碍的有前途的新疗法途径.
- 需要进一步进行严格的临床研究,以确定GLP-1RAs在AUD中的安全性和有效性.
- 针对GLP-1系统可能为管理AUD和相关并发症提供新的策略.
相关概念视频
Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
146
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
146
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
Oral Hypoglycemic Agents: Biguanides and Glitazones
162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
CNS Depressants: Alcohol and Nicotine
170
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
170
Enzyme Inhibition
77.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.8K


